Clinical trials: Carcinomas
Non Muscle Invasive Bladder Cancer
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.
- Trial name
- NCT02982395
- Testing
- Nanoxel®M, Mitomycin-C
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's…
- Conditions
- Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
- Trial name
- MDX1106-03 (NCT00730639)
- Testing
- BMS-936558 (MDX-1106)
- Where
- 13 sites in United States
- Volunteers
- 395 people
- Sponsor
- Bristol-Myers Squibb
Squamous Cell Carcinoma of the Oral Cavity
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
The primary objective of this open label Phase Ib/II trial is to evaluate the clinical and pharmacological activity of IPH2201 as a single-agent in treatment-naïve pre-operative patients with operable Squamous Cell Carcinoma of…
- Trial name
- NCT02331875
- Testing
- IPH2201, Standard Surgery, Postsurgical Adjuvant Therapy
- Where
- 3 sites in Germany, Spain
- Volunteers
- 3 people
- Sponsor
- Innate Pharma
Colorectal Cancer
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan…
- Trial name
- NCT00063141
- Testing
- cetuximab, Irinotecan
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 1,302 people
- Sponsor
- Eli Lilly and Company
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
This study comprises a Dose Escalation phase followed by a Dose Expansion phase. Dose Escalation part of the study will assess the safety and tolerability and determine the maximum tolerated dose (MTD) as the recommended Phase 2…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02606305
- Testing
- Mirvetuximab soravtansine, Bevacizumab, Carboplatin
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 264 people
- Sponsor
- ImmunoGen, Inc.
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387269
- Testing
- Anamorelin HCl
- Where
- 60 sites in United States, Belarus and 14 more
- Volunteers
- 484 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Colorectal Neoplasms, Melanoma
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
- Conditions
- Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma
- Trial name
- NCT00378482
- Testing
- CP-675,206 (Tremelimumab)
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer
To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.
- Trial name
- NSCLC (NCT03607188)
- Testing
- Alkotinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-small Cell Lung Carcinoma
BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This is a three-stage study, consisting of Phase Ia dose-escalation, Phase Ib dose expansion, and a Phase II component.
- Trial name
- NCT05393466
- Testing
- BPI-361175
- Volunteers
- 30 people
- Sponsor
- Xcovery Holdings, Inc.
Non-small Cell Lung Cancer
Barriers and Facilitators of Persistence With Adjuvant Osimertinib
This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage…
- Trial name
- SECURE (NCT07542210)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with.
- Trial name
- NCT07672223
- Testing
- SYS6010, Enlonstobart, Tislelizumab
- Volunteers
- 570 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care…
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases
- Trial name
- NCT03781934
- Testing
- MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib
- Where
- 18 sites in Belgium, South Korea and 2 more
- Volunteers
- 53 people
- Sponsor
- Medivir
Head and Neck Cancer
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had…
- Trial name
- NCT00617734
- Testing
- IMC-A12 (cixutumumab), cetuximab (Erbitux ®)
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.
- Trial name
- NCT05513664
- Testing
- Osimertinib
- Where
- 24 sites in China
- Volunteers
- 80 people
- Sponsor
- Shanghai JMT-Bio Inc.
Extensive-Stage Small Cell Lung Cancer
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
This is an open-label, multi-center Phase II study designed to evaluate the efficacy and safety of Surufatinib plus anti-PD-1/L1 as maintenance therapy after first-line standard of care in patients with ES-SCLC.
- Trial name
- NCT05509699
- Testing
- Surufatinib, Anti-PD-1/L1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hutchison Medipharma Limited
Hepatocellular Carcinoma (HCC)
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with…
- Trial name
- EMERALD-Y90 (NCT06040099)
- Testing
- Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure.
- Trial name
- NCT01903993
- Testing
- Docetaxel, Atezolizumab
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.